版本:
中国

BRIEF-Vanda and UCSF announce license agreement for CFTR activators and inhibitors

March 29 Vanda Pharmaceuticals Inc -

* Vanda and UCSF announce license agreement for CFTR activators and inhibitors

* Under terms of deal, vanda will pay UCSF an initial license fee of $1 million and will be responsible for all development costs

* In 2017 intends to complete technology transfer activities from UCSF,initiate ind enabling studies for several CFTR indications

* To acquire exclusive worldwide license from UCSF to develop, commercialize portfolio of cftr activators, inhibitors Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐